Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

leishmaniasis - Clinical Profile, Treatments & Trials | Kisho | Kisho

Rare Disease

leishmaniasis

MONDO:0011989

Also known as:cutaneous leishmaniasis (subtype)post kala-Azar dermal leishmaniasispost-kala-azar dermal infectious disease by leishmaniasis

Find Clinical TrialsTrials

Overview

Infectious disease that is transmitted through the bite of hematophagous female phlebotomine sand flies. The clinical spectrum ranges from asymptomatic to clinically overt disease which can remain localized to the skin or disseminate to the upper oral and respiratory mucous membranes or throughout the reticulo-endothelial system. Three main clinical syndromes have been described: visceral (or Kala-Azar; with fever, weight loss, hepatosplenomegaly), cutaneous, and mucocutaneous leishmaniasis (cutaneous or mucocutaneous ulceration).

Treatments1 FDA approved

Clinical Trials28 registered · 15 recruiting

Diagnosis

Biomarker and diagnostic research for leishmaniasis has been reported in the published literature.

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

1 FDA-approved treatment is available for leishmaniasis, including MILTEFOSINE (IMPAVIDO, approved 2014). An additional 2 compounds hold orphan drug designation.

Approved Therapies

Brand Name	Generic Name	Mechanism	Approved	Market Status

Prognosis

Estimated prevalence: 1-9 in 1,000,000 (Rare).

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

28 clinical trials registered, 15 recruiting. Interventions under study include drug therapy, other interventions, and medical devices. Pipeline includes 3 PHASE3, 8 PHASE2, 2 PHASE1. Research is primarily sponsored by academic and government institutions.

NCT ID	Title	Phase	Sponsor	Status
[NCT06550609](https://clinicaltrials.gov/study/NCT06550609)

Data assembled from 5 of 12 sources · Last updated Sep 20, 2026, 3:00 PM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

External Resources

Orphanet

European rare disease database

Orphanet:507

GARD

Genetic and Rare Diseases Info Center

GARD:6881

Questions for Your Care Team

→What are the benefits and potential side effects of IMPAVIDO for managing leishmaniasis?
→Are any of the 28 active clinical trials a good fit for my situation?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

Brand Name	Generic Name	Sponsor	Designated	Exclusivity End	Designation Status
parasite-selective proteasome inhibitor with potent activity against kinetoplastid parasites	parasite-selective proteasome inhibitor with potent activity against kinetoplastid parasites	Novartis Pharmaceuticals Corporation	2025	—	Designated
oleylphosphocholine	oleylphosphocholine	Oblita Therapeutics bvba	2013	—	Designated

Research Type	Count	% of Total
Research summaries	69	61%
Laboratory research	12	11%
Disease patterns and progression	12	11%
Patient case studies	10	9%
Other research	4	4%
Testing and diagnosis research	4	4%
Clinical study results	2	2%
New treatment approaches	1	1%

Kisho

leishmaniasis

Overview

Diagnosis

Treatment

Approved Therapies

Prognosis

Research Landscape

Medical References

External Resources

Orphanet

GARD

Questions for Your Care Team

Questions for Your Care Team

Orphan Drug Designations

Clinical Trials

Recent Publications

Latest News & Developments

Cutaneous leishmaniasis arising in a latent dermal sinus causing a dermoscopic dilemma.

Eprinomectin Inhibits Leishmania by Inducing Mitochondrial Dysfunction and Cell Cycle Arrest.

Local cytokine modulation and parasite visceralization during murine coinfection with Leishmania amazonensis and Schistosoma mansoni.

leishmaniasis

Overview

Diagnosis

Treatment

Approved Therapies

Prognosis

Research Landscape

Medical References

External Resources

Orphanet

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Orphan Drug Designations

Clinical Trials

Recent Publications

Latest News & Developments

Cutaneous leishmaniasis arising in a latent dermal sinus causing a dermoscopic dilemma.

Eprinomectin Inhibits Leishmania by Inducing Mitochondrial Dysfunction and Cell Cycle Arrest.

Local cytokine modulation and parasite visceralization during murine coinfection with Leishmania amazonensis and Schistosoma mansoni.